Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | RGS12 | O14924 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889714 | 1.00 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL3055513 | 1.00 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL1711563 | 1.00 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL29674753 | 1.00 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL430516 | 1.00 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL1417856 | 1.00 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL5598127 | 0.87 | LMNA (0.56) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL14474285 | 0.87 | LMNA (0.56) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL11602702 | 0.86 | IDO1 (0.54) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| Phosphoric Acid SCHEMBL4954578 | 0.86 | SRC (0.58) | LMNAADRA2CKDM4EADRA2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262953-A1 | THERMOPLASTIC ELASTOMER WITH EXCELLENT RESILIENCE AND HIGH STRENGTH AND PREPARATION METHOD THEREOF | NINGBO INSTITUTE OF MATERIALS TECHNOLOGY AND ENGINEERING, CHINESE ACADEMY OF SCIENCES (CN) | 2024-08-08 | — | — | US | claimed |
| US-8834934-B2 | Material encapsulation system | HAVILAND PRODUCTS COMPANY (US) | 2014-09-16 | — | — | US | claimed |
| US-7842485-B2 | Enhanced alcohol tolerant microorganism and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-11-30 | — | — | US | claimed |
| US-20070218533-A1 | Enhanced Alcohol Tolerant Microorganism and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-09-20 | — | — | US | claimed |
| US-20060110464-A1 | Material encapsulation system | HAVILAND PRODUCTS COMPANY | 2006-05-25 | — | — | US | claimed |
| EP-1596831-A2 | MATERIAL INCAPSULATION SYSTEM | Venture Management Alliance, LLC (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004073033-A2 | MATERIAL INCAPSULATION SYSTEM | VENTURE MANAGEMENT ALLIANCE, LLC (US) | 2004-08-26 | — | — | WO | claimed |
| EP-4737444-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12253482-B2 | Method for determining structure of substance in multicomponent sample | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2025-03-18 | — | — | US | disclosed |
| EP-4484435-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4065567-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240262953-A1 | THERMOPLASTIC ELASTOMER WITH EXCELLENT RESILIENCE AND HIGH STRENGTH AND PREPARATION METHOD THEREOF | NINGBO INSTITUTE OF MATERIALS TECHNOLOGY AND ENGINEERING, CHINESE ACADEMY OF SCIENCES (CN) | 2024-08-08 | — | — | US | disclosed |
| EP-0964004-A1 | New metallocene catalyst for olefin or styrene polymerization and polymerization method using the metallocene catalyst | Samsung General Chemicals Co., Ltd. (KR) | 1999-12-15 | — | — | EP | disclosed |
| EP-0658533-B1 | Process for the oxidation of primary and secondary alcohols to aldehydes and ketones and for the oxidation of 1,2-diols to alpha-ketols and alpha-diketones | SIGMA TAU IND FARMACEUTI (IT) | 1998-04-15 | — | — | EP | disclosed |
| US-5510538-A | USING O-IODOXYBENZOIC ACID AS OXIDIZING AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-04-23 | — | — | US | disclosed |
| EP-0658533-A1 | Process for the oxidation of primary and secondary alcohols to aldehydes and ketones and for the oxidation of 1,2-diols to alpha-ketols and alpha-diketones | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1995-06-21 | — | — | EP | disclosed |
| EP-0620500-A2 | Resist and pattern formation using the same | HITACHI, LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-4728429-A | Membrane permeation process for dehydration of organic liquid mixtures using sulfonated ion-exchange polyalkene membranes | CABASSO ISRAEL (US) | 1988-03-01 | — | — | US | disclosed |
| US-4087463-A | COBALT CARBONYL CATALYST | MONSANTO COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | LMNA 972/4885ADRA2C 4789/4885KDM4E 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.